Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China ,Taiwan ,United States ,Peking ,Beijing ,Hong Kong ,Macau ,Suzhou ,Jiangsu ,Chinese ,Innovent Biologics ,Adimab Incyte ,Yujie Zhou ,Yong Huo ,Eli Lilly ,Clinical Development Of Innovent ,Prnewswire Innovent Biologics Inc ,China Cardiovascular Health ,Capital Medical University ,Md Anderson Cancer Center ,National Science ,China National Medical Products Administration ,University First Hospital ,Innovent Or Company ,Incyte Corporation ,Innovent Biologics Inc ,National Medical Products Administration ,New Drug Application ,Technology Major Project ,New Drug ,Peking University First Hospital ,Beijing Anzhen Hospital ,Lei Qian ,Vice President ,Clinical Development ,Cardiovascular Health ,Disease Report ,Tafolecimab Injection ,Main Board ,Stock Exchange ,Hong Kong Limited ,Cancer Center ,Mainland China ,